CN Patent

CN111065411B — Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2023-03-10 · 3y expired

What this patent protects

本发明公开了PD‑1抗体和VEGFR抑制剂联合治疗小细胞肺癌的用途。具体而言，本发明公开了一种抗PD‑1抗体和VEGFR抑制剂联合在制备治疗小细胞肺癌的药物中的用途。

USPTO Abstract

本发明公开了PD‑1抗体和VEGFR抑制剂联合治疗小细胞肺癌的用途。具体而言，本发明公开了一种抗PD‑1抗体和VEGFR抑制剂联合在制备治疗小细胞肺癌的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN111065411B
Jurisdiction
CN
Classification
—
Expires
2023-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.